|
|
Vaccine Detail
|
Mouse gp100 Plasmid DNA Vaccine |
| Vaccine Information |
- Vaccine Name: Mouse gp100 Plasmid DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007528
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: gp100
- Pmel17
gene engineering:
- Adjuvant:
- Description: A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. (NCI05) (NCIT_C48410).
|
| Host Response |
|
|
| References |
NCIT_C48410: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48410]
Rakhmilevich et al., 2001: Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7(4); 952-961. [PubMed: 11309346].
|
|
